BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

219 related articles for article (PubMed ID: 34465768)

  • 1. A comprehensive risk score for effective risk stratification and screening of nasopharyngeal carcinoma.
    Zhou X; Cao SM; Cai YL; Zhang X; Zhang S; Feng GF; Chen Y; Feng QS; Chen Y; Chang ET; Liu Z; Adami HO; Liu J; Ye W; Zhang Z; Zeng YX; Xu M
    Nat Commun; 2021 Aug; 12(1):5189. PubMed ID: 34465768
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Plasma Epstein-Barr virus DNA and risk of nasopharyngeal carcinoma in a prospective seropositive population.
    Chen WJ; Xu WN; Wang HY; Chen XX; Li XQ; Xie SH; Lin DF; Cao SM
    BMC Cancer; 2021 Jun; 21(1):651. PubMed ID: 34074258
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A comparison of EBV serology and serum cell-free DNA as screening tools for nasopharyngeal cancer: Results of the Singapore NPC screening cohort.
    Tay JK; Siow CH; Goh HL; Lim CM; Hsu PP; Chan SH; Loh KS
    Int J Cancer; 2020 May; 146(10):2923-2931. PubMed ID: 31705522
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of Epstein-Barr Virus Serological Tools for the Screening and Risk Assessment of Nasopharyngeal Carcinoma: a Large Population-based Study.
    Guo J; Cui Z; Zheng Y; Li X; Chen Y
    Pathol Oncol Res; 2020 Oct; 26(4):2185-2190. PubMed ID: 32222897
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A novel and non-invasive approach utilising nasal washings for the detection of nasopharyngeal carcinoma.
    Tan GW; Sivanesan VM; Abdul Rahman FI; Hassan F; Hasbullah HH; Ng CC; Khoo AS; Tan LP
    Int J Cancer; 2019 Oct; 145(8):2260-2266. PubMed ID: 30698824
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of circulating EBV microRNA BART2-5p in facilitating early detection and screening of nasopharyngeal carcinoma.
    Jiang C; Chen J; Xie S; Zhang L; Xiang Y; Lung M; Kam NW; Kwong DL; Cao S; Guan XY
    Int J Cancer; 2018 Dec; 143(12):3209-3217. PubMed ID: 29971780
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Systematic comparison of plasma EBV DNA, anti-EBV antibodies and miRNA levels for early detection and prognosis of nasopharyngeal carcinoma.
    Tan LP; Tan GW; Sivanesan VM; Goh SL; Ng XJ; Lim CS; Kim WR; Mohidin TBBM; Mohd Dali NS; Ong SH; Wong CY; Sawali H; Yap YY; Hassan F; Pua KC; Koay CE; Ng CC; Khoo AS;
    Int J Cancer; 2020 Apr; 146(8):2336-2347. PubMed ID: 31469434
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cigarette smoking increases the risk of nasopharyngeal carcinoma through the elevated level of IgA antibody against Epstein-Barr virus capsid antigen: A mediation analysis.
    Hsu WL; Chien YC; Huang YT; Yu KJ; Ko JY; Lin CY; Tsou YA; Leu YS; Liao LJ; Chang YL; Su JY; Liu Z; Wang CP; Terng SD; Hua CH; Lee JC; Yang TL; Kate Hsiao CH; Wu MS; Tsai MH; Liu MJ; Lou PJ; Hildesheim A; Chen CJ;
    Cancer Med; 2020 Mar; 9(5):1867-1876. PubMed ID: 31925935
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Negative plasma Epstein-Barr virus DNA nasopharyngeal carcinoma in an endemic region and its influence on liquid biopsy screening programmes.
    Nicholls JM; Lee VH; Chan SK; Tsang KC; Choi CW; Kwong DL; Lam KO; Chan SY; Tong CC; So TH; Leung TW; Luk MY; Khong PL; Lee AW
    Br J Cancer; 2019 Oct; 121(8):690-698. PubMed ID: 31527689
    [TBL] [Abstract][Full Text] [Related]  

  • 10. VLDL and LDL Subfractions Enhance the Risk Stratification of Individuals Who Underwent Epstein-Barr Virus-Based Screening for Nasopharyngeal Carcinoma: A Multicenter Cohort Study.
    Zhou Z; Tang T; Li N; Zheng Q; Xiao T; Tian Y; Sun J; Zhang L; Wang X; Wang Y; Ye F; Chen Z; Zhang H; Zheng X; Cai Z; Liu L; Guan J
    Adv Sci (Weinh); 2024 Jun; 11(22):e2308765. PubMed ID: 38520712
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Natural Variations in BRLF1 Promoter Contribute to the Elevated Reactivation Level of Epstein-Barr Virus in Endemic Areas of Nasopharyngeal Carcinoma.
    Zhang JB; Huang SY; Wang TM; Dong SQ; He YQ; Zheng XH; Li XZ; Wang F; Jianbing M; Jia WH
    EBioMedicine; 2018 Nov; 37():101-109. PubMed ID: 30420297
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Incidence and mortality of nasopharyngeal carcinoma: interim analysis of a cluster randomized controlled screening trial (PRO-NPC-001) in southern China.
    Ji MF; Sheng W; Cheng WM; Ng MH; Wu BH; Yu X; Wei KR; Li FG; Lian SF; Wang PP; Quan W; Deng L; Li XH; Liu XD; Xie YL; Huang SJ; Ge SX; Huang SL; Liang XJ; He SM; Huang HW; Xia SL; Ng PS; Chen HL; Xie SH; Liu Q; Hong MH; Ma J; Yuan Y; Xia NS; Zhang J; Cao SM
    Ann Oncol; 2019 Oct; 30(10):1630-1637. PubMed ID: 31373615
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Genome sequencing analysis identifies Epstein-Barr virus subtypes associated with high risk of nasopharyngeal carcinoma.
    Xu M; Yao Y; Chen H; Zhang S; Cao SM; Zhang Z; Luo B; Liu Z; Li Z; Xiang T; He G; Feng QS; Chen LZ; Guo X; Jia WH; Chen MY; Zhang X; Xie SH; Peng R; Chang ET; Pedergnana V; Feng L; Bei JX; Xu RH; Zeng MS; Ye W; Adami HO; Lin X; Zhai W; Zeng YX; Liu J
    Nat Genet; 2019 Jul; 51(7):1131-1136. PubMed ID: 31209392
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cell-free EBV DNA as a biomarker during clinical management of nasopharyngeal carcinoma in a nonendemic region.
    Pramanik R; Arora S; Sharma P; Biswas A; Nayak B; Thakar A; Sharma A; Ghose S
    J Med Virol; 2022 Feb; 94(2):720-728. PubMed ID: 34750844
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Multiplex Epstein-Barr virus BALF2 genotyping detects high-risk variants in plasma for population screening of nasopharyngeal carcinoma.
    Miller JA; Sahoo MK; Yamamoto F; Huang C; Wang H; Zehnder JL; Le QT; Pinsky BA
    Mol Cancer; 2022 Jul; 21(1):154. PubMed ID: 35902864
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Genetic variants in NKG2D axis and susceptibility to Epstein-Barr virus-induced nasopharyngeal carcinoma.
    Viet NH; Trung NQ; Dong LT; Trung LQ; Espinoza JL
    J Cancer Res Clin Oncol; 2021 Mar; 147(3):713-723. PubMed ID: 33392659
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of plasma Epstein-Barr virus DNA load to distinguish nasopharyngeal carcinoma patients from healthy high-risk populations in Southern China.
    Ji MF; Huang QH; Yu X; Liu Z; Li X; Zhang LF; Wang P; Xie SH; Rao HL; Fang F; Guo X; Liu Q; Hong MH; Ye W; Zeng YX; Cao SM
    Cancer; 2014 May; 120(9):1353-60. PubMed ID: 24477877
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Detection of Epstein-Barr virus (EBV)-encoded microRNAs in plasma of patients with nasopharyngeal carcinoma.
    Gao W; Wong TS; Lv KX; Zhang MJ; Tsang RK; Chan JY
    Head Neck; 2019 Mar; 41(3):780-792. PubMed ID: 30548946
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Quantification of Epstein-Barr virus DNA load in nasopharyngeal brushing samples in the diagnosis of nasopharyngeal carcinoma in southern China.
    Zheng XH; Lu LX; Li XZ; Jia WH
    Cancer Sci; 2015 Sep; 106(9):1196-201. PubMed ID: 26082292
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sequencing Analysis of Plasma Epstein-Barr Virus DNA Reveals Nasopharyngeal Carcinoma-Associated Single Nucleotide Variant Profiles.
    Lam WKJ; Ji L; Tse OYO; Cheng SH; Jiang P; Lee PHP; Lin SV; Hui EP; Ma BBY; Chan ATC; Chan KCA; Chiu RWK; Lo YMD
    Clin Chem; 2020 Apr; 66(4):598-605. PubMed ID: 32191318
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.